Novavax | NVAX - Net Income


Novavax reported $17.53M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Adma Biologics USD 45.33M 4.05M Mar/2026
Agenus USD 39.17M 49.8M Mar/2026
AstraZeneca USD 2.51B 573M Jun/2026
BioCryst Pharmaceuticals USD 78.4M 167.45M Jun/2026
Cassava Sciences USD -10.33M 2.21M Mar/2026
Geron USD -3.64M 27.5M Mar/2026
GlaxoSmithKline GBP 435M 1.3B Jun/2026
MannKind USD -16.62M 671K Mar/2026
Merck USD -1.34B 2.9B Jun/2026
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Moderna USD -1.34B 517M Mar/2026
Novartis USD 3.16B 747M Mar/2026
Novavax USD 17.53M 219.91M Dec/2025
Pfizer USD -248M 2.94B Jun/2026
Sanofi EUR 343M 1.27B Jun/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
TG Therapeutics USD 7.78M 12M Jun/2026